La Jolla Pharmaceuticals (LJPC) is undergoing a critical transition at this point in time as it seemingly kills off R&D to focus on commercialization. At the same time, overall levels of transparency are on the lower end of the spectrum, which puts LJPC in a highly speculative position.
Some recent history
If nothing changes, LJPC is largely going to be a single product company going forward. In December 2017, it had won its first FDA approval for Giapreza, a vasopressor for use in shock. Things were looking upbeat as LJPC looked to commercialize Giapreza